Holliston, Massachusetts

Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET

Retrieved on: 
Monday, July 19, 2021

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Key Points: 
  • HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
  • You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 6293853.
  • The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website.
  • Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.

Biostage Strengthens Board of Directors with Appointment of Herman Sanchez

Retrieved on: 
Monday, January 25, 2021

HOLLISTON, Mass., Jan. 25, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it appointedHerman Sanchezas an independent director to its Board of Directors.

Key Points: 
  • HOLLISTON, Mass., Jan. 25, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it appointedHerman Sanchezas an independent director to its Board of Directors.
  • "We are very excited to announce the addition of the seasoned life sciences industry expert to Biostage," said Jason Chen, Chairman of Biostage.
  • On behalf of Biostage's Board of Directors and management team, I sincerely welcome Mr. Sanchez to our Board of Directors at this important moment of the Company.
  • Mr. Sanchez commented, "I am excited to join the Board of Directors of Biostage and collaborate with the Board and executive team.

Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference

Retrieved on: 
Monday, November 16, 2020

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Companys 9th Annual Discovery One-on-One Conference.

Key Points: 
  • HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Companys 9th Annual Discovery One-on-One Conference.
  • The virtual event will take place on Wednesday, November 18, 2020 with virtual investor meetings held throughout the day.
  • A copy of the materials to be presented at the conference will be available on the investor relations page of the Harvard Bioscience website on November 18, 2020 at 8:00 AM ET.
  • Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.

Harvard Bioscience Announces First Quarter 2020 Financial Results

Retrieved on: 
Tuesday, May 5, 2020

HOLLISTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the three months ended March 31, 2020.

Key Points: 
  • HOLLISTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the three months ended March 31, 2020.
  • Jim Green, Chairman and CEO said, Our first quarter results were negatively impacted by the Covid-19 pandemic.
  • Please see Use of Non-GAAP Financial Information for additional information regarding our use of such adjusted financial information.
  • Due to the significant uncertainties related to the impact of the Covid-19 pandemic, the Company is withdrawing its full-year 2020 financial guidance previously provided on February 26, 2020.

Biostage Reports 2019 Financial Results

Retrieved on: 
Friday, March 27, 2020

HOLLISTON, Mass., March 27, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG)("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2019.

Key Points: 
  • HOLLISTON, Mass., March 27, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG)("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2019.
  • At December 31, 2019, the Company had operating cash on-hand of $0.9 million and no debt.
  • The Company used net cash in operations of $6.1 million during the year ended December 31, 2019.
  • The Company's results may also be affected by factors of which the Company is not currently aware.

Harvard Bioscience Announces Executive Appointment

Retrieved on: 
Thursday, October 31, 2019

HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green.

Key Points: 
  • HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green.
  • Singh, formerly a long-tenured executive at Analogic Corporation, has more than 20 years of business strategy and operations experience with global businesses.
  • Most recently, he served as President of Analogics Power and Robotic Motion Business, and prior to that role served in various executive leadership roles at Analogic.
  • Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science.

Harvard Bioscience Announces Executive Appointment

Retrieved on: 
Monday, October 21, 2019

HOLLISTON, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green.

Key Points: 
  • HOLLISTON, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green.
  • This is a key appointment to the leadership team.
  • Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science.
  • We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China.

Maestro Holdings Acquires Foxtec Corporation

Retrieved on: 
Tuesday, September 10, 2019

HOLLISTON, Mass., Sept. 10, 2019 /PRNewswire/ --Maestro Holdings, an independent distributor supporting IT lifecycle asset management, is expanding its asset disposal service offerings globally through the acquisition of Foxtec Corporation, a leading distributor of IT-related components and asset recovery services.

Key Points: 
  • HOLLISTON, Mass., Sept. 10, 2019 /PRNewswire/ --Maestro Holdings, an independent distributor supporting IT lifecycle asset management, is expanding its asset disposal service offerings globally through the acquisition of Foxtec Corporation, a leading distributor of IT-related components and asset recovery services.
  • "Our combined team now provides both the highest quality certified processing facilities and the crucial remarketing component that results in delivering the best return on our customers' assets," said Jonathan Gerber, chief executive officer of Maestro Holdings.
  • The business will continue operating as Foxtec Corporation and now deliver over 50 years of industry experience and premier ITAD infrastructure.
  • Foxtec Corporationis an independent distributor of IT-related components and services that has established itself as an industry leader over the last 27 years in business.

Biostage Reports First Quarter 2019 Financial Results

Retrieved on: 
Tuesday, May 14, 2019

HOLLISTON, Mass., May 14, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for the three months ended March 31, 2019.

Key Points: 
  • HOLLISTON, Mass., May 14, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for the three months ended March 31, 2019.
  • The Company used net cash in operations of approximately of $1.2 million during the quarter ended March 31, 2019.
  • Dr. Wigle announced the details speaking at the Tech-Con 2019 meeting hosted by the Society of Thoracic Surgeons on January 26, 2019.
  • Biostage will be hosting a conference call and webcast today at 9:00 am ET to review its operational progress and financial report.

Biostage Reports 2018 Third Quarter Financial Results

Retrieved on: 
Thursday, November 8, 2018

HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for the three and nine months ended September 30, 2018.

Key Points: 
  • HOLLISTON, Mass., Nov. 8, 2018 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for the three and nine months ended September 30, 2018.
  • The Company also generated approximately $5.0 million, net, from financing activities during the first nine months of 2018.
  • During the third quarter of 2018, the Company advanced its operating programs aimed at bringing its potentially life-changing Cellframe technology to underserved patient populations.
  • The Company's results may also be affected by factors of which the Company is not currently aware.